New immune therapy enters first human trial for Tough-to-Treat lung cancer

NCT ID NCT03319940

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

Summary

This is an early-stage safety study testing a new drug called tarlatamab in people with advanced small cell lung cancer that has returned or stopped responding to standard chemotherapy. The main goals are to find a safe dose, check for side effects, and see how the drug behaves in the body. The drug is designed to help the patient's own immune system recognize and attack the cancer cells.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Biokinetica SA

Józefów, 05-410, Poland
Centre Hospitalier Universitaire Vaudois

Lausanne, 1011, Switzerland
Chris OBrien Lifehouse

Camperdown, New South Wales, 2050, Australia
Christie Hospital

Manchester, M20 4BX, United Kingdom
City of Hope National Medical Center

Duarte, California, 91010, United States
Europejskie Centrum Zdrowia Otwock Szpital imienia Fryderyka Chopina

Otwock, 05-400, Poland
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Gustave Roussy

Villejuif, 94805, France
Henry Ford Health System

Detroit, Michigan, 48202, United States
Hospital Clinic i Provincial de Barcelona

Barcelona, Catalonia, 08036, Spain
Hospital Universitari Vall d Hebron

Barcelona, Catalonia, 08035, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Hospital Universitario Ramon y Cajal

Madrid, 28034, Spain
John Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21287, United States
Kantonsspital St Gallen

Sankt Gallen, 9007, Switzerland
Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, 80756, Taiwan
Landeskrankenhaus Salzburg

Salzburg, 5020, Austria
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation

Taoyuan District, 33305, Taiwan
Maastricht Universitair Medisch Centrum

Maastricht, 6229 HX, Netherlands
Medizinische Universitaet Graz

Graz, 8036, Austria
Memorial Sloan Kettering Cancer Center

New York, New York, 10021, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
National Cancer Center Hospital

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East

Kashiwa-shi, Chiba, 277-8577, Japan
Nederlands Kanker Instituut Antoni van Leeuwenhoekziekenhuis

Amsterdam, 1066 CX, Netherlands
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
Prince of Wales Hospital

Shatin, New Territories, Hong Kong
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic

Columbus, Ohio, 43210, United States
Tri-Service General Hospital

Taipei, 11490, Taiwan
Universitaetsklinikum Wuerzburg

Würzburg, 97078, Germany
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Pittsburgh Medical Center Cancer Pavillion

Pittsburgh, Pennsylvania, 15232, United States
Wakayama Medical University Hospital

Wakayama, Wakayama, 641-8510, Japan
Washington University

St Louis, Missouri, 63110-1093, United States
Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Yale New Haven Hospital

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

SMALL CELL LUNG CARCINOMA